Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Todd Neale

September 21, 2022

Presentation TCT 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Sungsoo Cho

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

Todd Neale

September 18, 2022

Presentation TCT 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presenter: Johny Nicolas

September 17, 2022

Presentation TCT 2022

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

Presenter: Ajay Kirtane

September 17, 2022

Presentation TCT 2022

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

Presenter: Jeehoon Kang

September 17, 2022

Presentation TCT 2022

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

Presenter: Giulia Masiero

September 17, 2022

Presentation TCT 2022

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Presenter: Toshiki Kuno

September 17, 2022

Advertisement

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content